预防遗传性血管水肿发作：贝罗司他胶囊显奇效

Hereditary angioedema (HAE) is a rare autosomal dominant disease, first reported by Osler in 1888. Its pathogenesis is a defect in the complement 1 inhibitory factor (C1INH) gene, resulting in low plasma C1-NH content and/or function. So far, more than 200 C1NH gene mutations related to the onset of HAE have been reported at home and abroad, with great heterogeneity. The genetic characteristics of HAE are autosomal dominant inheritance, but about 25% are caused by gene mutations and there is no family history. Pharmaceutical company BioCryst recently announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the sales and production license of ORLADEYO () for the prevention of angioedema (HAE) in adults and children over 12 years old.

Based on data from APeX-J and APeX-2 clinical trials. Japan's APeX-J trial met its primary endpoint, with patients receiving berosostat capsules experiencing a significant reduction in the frequency of HAE attacks compared with placebo (p = 0.003). Moreover, berosostat capsules are safe and generally tolerated in trials.

Observed in the experiment were abnormal liver function indicators, back pain, gastroesophageal reflux disease, abdominal pain, vomiting, short-term itchy rash, heart rhythm problems, diarrhea, etc. Here, the editor solemnly wants to tell all patients who are using berosstat capsules that it is recommended that you take the medicine during the medication period. Always use medication correctly in accordance with the doctor's instructions. Do not listen to others who say that doubling the dose of a drug can improve the therapeutic effect, and do not believe in rumors that lowering the dose can reduce side effects. Only by strictly following the doctor's instructions can you achieve the best effect on your own treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.